CB2 Insights Inc (CSE:CBII) (OTMKTS:CBIIF), the cannabis research and education group, unveiled director changes on Wednesday, including the appointment of data healthcare specialist Tom Brogan as an independent member of the board.
Brogan will replace outgoing directors David Danziger and Gerry Goldberg, who wish to pursue other opportunities, the firm said.
The current independent director Norton Singhavon has been named as interim chairman of the board with immediate effect.
"Mr. Brogan’s extensive experience in building innovative data-driven healthcare technology companies combined with global operations exposure in the Life Sciences sector with leading names in Contract Research and Data Analytics, will be [a] key addition to our Board and leadership team, fostering the growth of CB2," said Prad Sekar, the CEO at CB2 Insights.
The firm is confident that Brogan’s track record will provide CB2 with "exceptional perspective in maximizing our strategies, and exposure to traditional pharma partners for future commercialization", it said.
Brogan is currently CEO and chairman at Vestrum Health, the electronic healthcare record company which delivers information to pharma manufacturers, doctors' practices and others.
Before that, he was the founder of Brogan Consulting, acquired by IMS in 2010, now IQVIA, one of the world’s largest Contract Research Organizations (CROs).
"I look forward to being part of the CB2’s leadership team and advising the company through the next growth phase,” said Brogan.
Unique business strategy
“As I have experienced before, the company’s unique business strategy is proving it will be a critical contributor to advancing the use cannabinoid-based medicines into traditional healthcare through technology, data, and supporting clinical trials – an area that is lacking in the current market."
CB2 Insights has active technology, data and research projects in North America, the UK and Colombia.
It can support licensed producers, multi-state operators from pre-clinical trial activities through to product commercialization.
Shares in Toronto advanced 4.17% to stand at C$0.12 each.
Contact the author at [email protected]